Researchclopedia

Research Researchers Institutions Topics Submit About

Command Palette

Search for a command to run...

Researchclopedia

Research Researchers Institutions About

© 2026 Researchclopedia. Powered by OpenAlex under CC0 license.

Sarah Schlief | Researchclopedia

Back to researchers

Sarah Schlief

Bayer (Germany)

11

Works

89

Citations

5

h-index

3

i10-index

Research Topics

Retinopathy of Prematurity Studies Neonatal Respiratory Health Research Colorectal Cancer Treatments and Studies

Affiliations

Bristol-Myers Squibb (Germany)2007–2007

Bayer (Germany)2016–2026

Charité - Universitätsmedizin Berlin2009–2009

Top Works

Phase 1 dose-escalation and pharmacokinetic study of regorafenib in paediatric patients with recurrent or refractory solid malignancies

Birgit Geoerger,Bruce Morland,et al.

202131 citations

Hepatocellular Carcinoma Treatment and Prognosis

Lung Cancer Treatments and Mutations

Antimony-trioxide- and arsenic-trioxide-induced apoptosis in myelogenic and lymphatic cell lines, recruitment of caspases, and loss of mitochondrial membrane potential are enhanced by modulators of the cellular glutathione redox system

Susan Lösler,Sarah Schlief,et al.

200923 citations

Intravitreal Aflibercept vs Laser Therapy for Retinopathy of Prematurity

Andreas Stahl,Hidehiko Nakanishi,et al.

202421 citations

Systemic exposure to aflibercept after intravitreal injection in premature neonates with retinopathy of prematurity: results from the FIREFLEYE randomized phase 3 study

Andreas Stahl,Noriyuki Azuma,et al.

20246 citations

Phase I dose-escalation and pharmacokinetic (PK) study of regorafenib in pediatric patients with recurrent or refractory solid malignancies.

Birgit Geoerger,Bruce Morland,et al.

20165 citations

Correction: Systemic exposure to aflibercept after intravitreal injection in premature neonates with retinopathy of prematurity: results from the FIREFLEYE randomized phase 3 study

Andreas Stahl,Noriyuki Azuma,et al.

20242 citations

Correlation of efficacy and safety outcomes with regorafenib exposure in patients with hepatocellular carcinoma

Adriaan Cleton,Kristina Graudenz,et al.

20171 citations

Compassionate Use Experience with Dasatinib Therapy in Patients after Imatinib and/or Nilotinib Failure.

Bettina A. Gunawardena,Sarah Schlief,et al.

20070 citations

Time course of treatment-emergent adverse events (TEAEs) in the randomized, controlled phase 3 RESORCE trial of regorafenib for patients with hepatocellular carcinoma progressing on sorafenib treatment.

Philippe Merle,Alessandro Granito,et al.

20170 citations